| |
Cell and gene therapies for rare diseases often present unique obstacles that can be overcome using in silico approaches. Learn how in our on-demand webinar, and meet us at BIO to discuss how Premier Consulting can advance your CGT program to its next milestone. Premier Consulting. Built for Biotech℠.
|
|
Today's Big NewsMay 22, 2023 |
|
July 18-19, 2023 | Jersey City, NJ
More panels and case studies providing real, practical experiences and solutions, including topics surrounding Investor Relations and Government Affairs. Save $500 when you Register before May 30th!
|
|
| By Nick Paul Taylor Novartis is buying a gene therapy candidate from the cash-constrained Avrobio, striking an unusual deal that will see it pay $87.5 million without committing milestones or royalties to land the clinical-phase asset. The news comes months after Novartis was reported to be lining up a takeover of Avrobio. |
|
|
|
By James Waldron Having tasted blockbuster success with its IBS drug Linzess, Ironwood Pharmaceuticals is willing to pay $1 billion for the chance to make lightning strike twice. |
By Annalee Armstrong Fierce Biotech is once again seeking your nominations for the best, most exciting and innovative private biotechs. |
By Annalee Armstrong Weeks after closing a deal to buy Jounce Therapeutics, Concentra Biosciences is rebounding to pick up another struggling biotech, this time COVID-19-focused Atea Pharmaceuticals. |
|
Explore the whole transcriptome with a prep that generates libraries in under 4.5 hours - including rRNA depletion - and delivers superior gene detection sensitivity with FFPE and low inputs. View the Data.
|
|
By Annalee Armstrong Storm clouds are brewing for Rain Oncology after its lead asset failed to improve progression-free survival versus chemotherapy in a phase 3 trial of patients with liposarcoma. |
By Nick Paul Taylor Hepion Pharmaceuticals is claiming success for its phase 2 nonalcoholic steatohepatitis (NASH) trial. But with the study lacking a control arm, relying on an investigational diagnostic and mostly only achieving significant results at the highest dose, plenty of questions about the candidate remain unanswered. |
By Max Bayer Apnimed is maintaining its momentum, hitting the primary endpoint in a phase 2 study testing its oral sleep apnea med. The company is now planning on launching a phase 3 trial in the second half of the year. |
By Gabrielle Masson Hoping to lighten its load, RedHill Biopharma has thrown a phase 3 lung disease program from its pack in attempts to save resources and carry its COVID-19 med to the top. |
By Fraiser Kansteiner,Zoey Becker,Angus Liu,Eric Sagonowsky,Kevin Dunleavy Many of the drugs on this list will be well known to industry watchers. Last year, bluebird, plus CSL Behring and uniQure, nabbed three gene therapy nods in quick succession. Elsewhere, Novartis’ established gene therapy Zolgensma continues to orbit the top of the price rankings. |
By Ben Adams Any publicity, even bad publicity, is good. So goes the old saying, but, for Novo Nordisk, too much publicity for its popular weight-loss drug Wegovy is becoming a bad thing, forcing the Danish drugmaker to turn off the marketing tap for the drug. |
By Andrea Park According to the FDA, Beta Bionics’ system is not only an improvement over standard, non-algorithm-guided insulin pump therapy, but is also easier to set up than other currently available artificial pancreas systems. |
By Kevin Dunleavy Sanofi is touting the advantages of Dupixent in COPD, along with the prospects of its other pipeline treatments for respiratory disorders. These include SAR’765, which targets two pathways and has the potential to become the most effective biologic in asthma, the company said. |
By Frank Diamond The CMS deadline for health insurance plans to make all healthcare price data consumer friend-ly is Jan. 1, 2024. Elevance Health argues that all elements in the cost equation need to be considered. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we''ll discuss the recent biopharma layoff trends, plus Elizabeth Holmes, Sarepta Therapeutics, Abbott's FDA approval, and the rest of the week's headlines. |
|
|---|
|
|
| WhitepaperChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations. Sponsored by: Elucidata Corp., Cloud SAAS in Life Sciences R&D |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookDiscover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success. Sponsored by: EvidentIQ |
| Research What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| WhitepaperThis paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| |
|
